Jade Biosciences, Inc. (JBIO) Financial Ratios
6 years of historical data (2020–2025) · Healthcare · Biotechnology
EV/EBITDA
N/A
—
5yr avg: N/A
P/FCF
N/A
—
5yr avg: N/A
P/B Ratio
↓
1.52
↓-50% vs avg
5yr avg: 3.04
30Y Low1.0·High5.7
ROE
↓
-62.3%
-19% vs avg
5yr avg: -52.4%
30Y Low-327%·High-26%
Debt/EBITDA
N/A
—
5yr avg: N/A
Percentile shows where the current value sits in 30-year historical distribution. Sparklines show 5-year trend.
JBIO Valuation Multiples
Price-based multiples — how expensive the stock is relative to earnings, sales, book value, and cash flow
Jade Biosciences, Inc. currently has a negative P/E ratio, indicating the company is operating at a loss on a trailing-twelve-month basis.
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 |
|---|---|---|---|---|---|---|---|
| Market Cap | $525M | $484M | $76M | $596M | $717M | $288M | — |
| Enterprise Value | $437M | $396M | $42M | $573M | $696M | $234M | — |
| P/E Ratio → | -3.96 | — | — | — | — | — | — |
| P/S Ratio | — | — | — | — | — | — | — |
| P/B Ratio | 1.52 | 1.46 | 0.99 | 5.44 | 5.66 | 1.67 | — |
| P/FCF | — | — | — | — | — | — | — |
| P/OCF | — | — | — | — | — | — | — |
P/E links to full P/E history page with 30-year chart
JBIO EV Ratios
Enterprise-value multiples — capital-structure-neutral measures of total business value
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 |
|---|---|---|---|---|---|---|---|
| EV / Revenue | — | — | — | — | — | — | — |
| EV / EBITDA | — | — | — | — | — | — | — |
| EV / EBIT | — | — | — | — | — | — | — |
| EV / FCF | — | — | — | — | — | — | — |
JBIO Profitability
Margins and return-on-capital ratios measuring operating efficiency
A negative ROE of -62.3% indicates the company is currently destroying shareholder equity.
Margins
Full margin charts and quarterly trend are on the Earnings History page
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 |
|---|---|---|---|---|---|---|---|
| Gross Margin | — | — | — | — | — | — | — |
| Operating Margin | — | — | — | — | — | — | — |
| Net Profit Margin | — | — | — | — | — | — | — |
Return on Capital
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 |
|---|---|---|---|---|---|---|---|
| ROE | -62.3% | -62.3% | -74.9% | -63.9% | -34.4% | -26.2% | -326.8% |
| ROA | -59.2% | -59.2% | -67.0% | -57.5% | -33.2% | -25.5% | -203.8% |
| ROIC | -59.2% | -59.2% | -86.2% | -63.6% | -35.6% | -29.5% | — |
| ROCE | -55.4% | -55.4% | -80.1% | -68.6% | -35.5% | -26.2% | -302.2% |
JBIO Leverage & Debt
Solvency and debt-coverage ratios — lower is generally safer
The company holds a net cash position — cash of $88M exceeds total debt of $724000, providing substantial financial flexibility for buybacks, acquisitions, or weathering downturns.
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 |
|---|---|---|---|---|---|---|---|
| Debt / Equity | 0.00 | 0.00 | 0.01 | 0.01 | 0.01 | 0.00 | — |
| Debt / EBITDA | — | — | — | — | — | — | — |
| Net Debt / Equity | — | -0.26 | -0.44 | -0.21 | -0.17 | -0.31 | -1.55 |
| Net Debt / EBITDA | — | — | — | — | — | — | — |
| Debt / FCF | — | — | — | — | — | — | — |
| Interest Coverage | — | — | — | — | — | — | -127.15 |
Net cash position: cash ($88M) exceeds total debt ($724000)
JBIO Liquidity & Efficiency
Short-term solvency ratios and asset-utilisation metrics
Jade Biosciences, Inc.'s current ratio of 20.33x is well above the 1.0 safety threshold, indicating strong short-term liquidity with ample room to cover current liabilities. The current ratio has improved from 7.04x to 20.33x over the past 3 years.
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 |
|---|---|---|---|---|---|---|---|
| Current Ratio | 20.33 | 20.33 | 20.93 | 7.04 | 16.90 | 68.37 | 2.64 |
| Quick Ratio | 20.33 | 20.33 | 20.93 | 7.04 | 16.90 | 68.37 | 2.64 |
| Cash Ratio | 20.33 | 20.33 | 20.54 | 6.94 | 16.60 | 65.64 | 2.58 |
| Asset Turnover | — | — | — | — | — | — | — |
| Inventory Turnover | — | — | — | — | — | — | — |
| Days Sales Outstanding | — | — | — | — | — | — | — |
JBIO Shareholder Yields
Earnings, FCF, buyback, and dividend yields — total returns to shareholders
Jade Biosciences, Inc. does not currently pay a dividend and has no material buyback yield, reinvesting earnings back into the business.
Dividends
Full dividend history and growth charts are on the Dividend History page
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 |
|---|---|---|---|---|---|---|---|
| Dividend Yield | — | — | — | — | — | — | — |
| Payout Ratio | — | — | — | — | — | — | — |
Total Shareholder Return Metrics
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 |
|---|---|---|---|---|---|---|---|
| Earnings Yield | — | — | — | — | — | — | — |
| FCF Yield | — | — | — | — | — | — | — |
| Buyback Yield | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | — |
| Total Shareholder Yield | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | — |
| Shares Outstanding | — | $31M | $816634 | $752332 | $699202 | $697439 | $697439 |
Peer Comparison
Compare JBIO with 10 similar companies in its peer group
| Company | Market Cap | P/E | EV/EBITDA | P/FCF | Gross Margin | Op Margin | ROE | ROIC | Debt/EBITDA |
|---|---|---|---|---|---|---|---|---|---|
 JBIOYou | $525M | -4.0 | — | — | — | — | -62.3% | -59.2% | — |
 KRYS | $9B | 47.0 | 53.6 | 50.2 | 92.6% | 41.5% | 18.9% | 18.0% | 0.1 |
 RCUS | $2B | -7.1 | — | — | 96.0% | -156.3% | -63.3% | -64.1% | — |
 IMVT | $7B | -11.9 | — | — | — | — | -64.8% | — | — |
 ARQT | $3B | -189.2 | — | — | 90.2% | -3.3% | -9.3% | -5.2% | — |
 DAWN | $2B | -20.7 | — | — | 89.1% | -80.8% | -22.7% | -30.5% | — |
 REGN | $64B | 14.7 | 15.3 | 15.6 | 85.4% | 24.9% | 14.9% | 8.9% | 0.7 |
 ABBV | $398B | 94.8 | 16.3 | 22.3 | 70.2% | 32.8% | 6214.7% | 23.9% | 2.4 |
 SNDX | $2B | -5.4 | — | — | 96.0% | -158.4% | -161.8% | -54.2% | — |
 PRAX | $7B | -18.4 | — | — | — | — | -45.8% | -65.0% | — |
 KYMR | $7B | -22.5 | — | — | 100.0% | -891.3% | -25.8% | -24.9% | — |
| Healthcare Median | — | 23.1 | 14.4 | 19.0 | 64.0% | -4.2% | -32.6% | -11.2% | 3.2 |
Peer selection based on competitive and market overlap. Compare multiple stocks →
Download Financial Ratios Data
Includes 30+ ratios · 6 years · Updated daily
What if you invested $1,000 in JBIO 10 years ago?
Total return calculator · dividends reinvested
Calculate ReturnsHow much would $100/month in JBIO be worth today?
Dollar cost averaging vs lump sum · see how regular investing compounds over time
Run the NumbersIs JBIO Undervalued Right Now?
DCF intrinsic value, peer multiples, and analyst estimates — see what the stock is really worth.
View ValuationJBIO vs KRYS — which is the better buy?
Side-by-side revenue, margins, P/E and 10-year returns vs Krystal Biotech, Inc..
Compare NowJBIO — Frequently Asked Questions
Quick answers to the most common questions about buying JBIO stock.
What is Jade Biosciences, Inc.'s P/E ratio?
Jade Biosciences, Inc.'s current P/E ratio is -4.0x. This places it at the 50th percentile of its historical range.
What is Jade Biosciences, Inc.'s ROE?
Jade Biosciences, Inc.'s return on equity (ROE) is -62.3%. The historical average is -98.1%.
Is JBIO stock overvalued?
Based on historical data, Jade Biosciences, Inc. is trading at a P/E of -4.0x. This is at the 50th percentile of its historical P/E range. Compare with industry peers and growth rates for a complete picture.